Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02214225 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.
A Phase 3 study, sponsored by Seqirus.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,484
- Enrollment target
NCT02214225 is a Phase 3 study that has completed, run by Seqirus. The registered enrollment target is 3,484 participants.
The verdict
NCT02214225, a Phase 3 study, has completed, sponsored by Seqirus.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,484 participants
- Enrollment target
Study Summary
This is a study to assess the immune (antibody) response and safety of a bioCSL split virion, inactivated quadrivalent influenza vaccine, in comparison with a US licensed 2014/2015 trivalent influenza vaccine (bioCSL TIV-1), and a trivalent influenza vaccine containing the alternate B strain (bioCSL TIV-2), in healthy adult volunteers aged 18 years and above.
Interventions
- BIOLOGICAL Quadrivalent Influenza Vaccine (QIV)
- BIOLOGICAL Trivalent Influenza Vaccine (TIV-1)
- BIOLOGICAL Trivalent Influenza Vaccine (TIV-2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,484 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02214225
The ClinicalTrials.gov registry entry for NCT02214225 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,484 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seqirus, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Quadrivalent Influenza Vaccine (QIV) is the first listed.
NCT02214225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02214225 about?
NCT02214225 is a clinical study titled "A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.". This is a study to assess the immune (antibody) response and safety of a bioCSL split virion, inactivated quadrivalent influenza vaccine, in comparison with a US licensed 2014/2015 trivalent influenza vaccine (bioCSL TIV-1), and a trivalent influenza vaccine containing the alternate B strain (bioCSL...
What is the current status of trial NCT02214225?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,484 participants. The study started on 2014-08. Estimated completion is 2015-04.
What interventions are being tested in trial NCT02214225?
The interventions under investigation include: Quadrivalent Influenza Vaccine (QIV) (BIOLOGICAL), Trivalent Influenza Vaccine (TIV-1) (BIOLOGICAL), Trivalent Influenza Vaccine (TIV-2) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02214225?
This trial is sponsored by Seqirus, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.